Skip to content

US · FULC · BIOTECHNOLOGY

Fulcrum Therapeutics, Inc. (FULC) intrinsic value and stock valuation

$3.69as of 2026-11-21 · Mkt cap 204M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Fulcrum Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values FULC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FULC’s statements →

Fulcrum Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 fulcrumtx.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-74.88M
20172025
Free cash flow
-$-60.38M
20172025
Total equity
$349M+29.7% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$80M$2.81M$6.34M$19.2M
Operating income-$-84.77M-$-21.9M-$-110.66M-$-112.56M-$-81.05M
Net income-$-74.88M-$-9.72M-$-97.33M-$-109.87M-$-80.85M
EPSd-$-1.18M-$-156.82K-$-1.59M-$-2.44M-$-2.29M
Operating cash flow-$-60.06M-$-2.22M-$-90.97M-$-97.05M-$-78.48M
Capital expenditure-$-310K-$-280K-$-510K-$-1.96M-$-1.71M
Free cash flow-$-60.38M-$-2.5M-$-91.47M-$-99.01M-$-80.19M
Total assets$366.3M$260.7M$257.7M$226.7M$235M
Total debt$6.44M$8.63M$10.8M$13.4M$0.00
Net debt-$-191.09M-$-49.58M-$-14.74M-$-21.68M-$-35.41M
Total equity$349M$243M$235.2M$198.9M$211.5M
Cash and short-term investments$352.3M$241M$236.2M$202.9M$218.2M
Income statement
20252024202320222021
Revenue$0.00$80M$2.81M$6.34M$19.2M
Cost of revenue$1.39M$63.4M$71.8M$76.8M$69.7M
Gross profit-$-1.39M$16.6M-$-69M-$-70.44M-$-50.54M
Research and development expenses$56.1M$63.4M$71.8M$76.8M$69.7M
Selling, general and administrative expenses$28.7M$36.5M$41.7M$41.7M$30.5M
Other expenses-$-1.39M-$-61.32M-$-71.8M-$-76.36M-$-69.7M
Operating expenses$83.4M$38.5M$41.7M$42.1M$30.5M
Cost and expenses$84.8M$101.9M$113.5M$118.9M$100.2M
Interest income$0.00$0.00$0.00$0.00$210K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.39M$1.59M$2.17M$2.41M$2.52M
Ebitda-$-73.49M-$-18.24M-$-95.16M-$-109.72M-$-78.33M
Operating income-$-84.77M-$-21.9M-$-110.66M-$-112.56M-$-81.05M
Total other income/expenses, net$9.89M$12.2M$13.3M$2.69M$210K
Income before tax-$-74.88M-$-9.72M-$-97.33M-$-109.87M-$-80.85M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-74.88M-$-9.72M-$-97.33M-$-109.87M-$-80.85M
Weighted average shares outstanding$63.4M$62M$61.3M$45M$35.4M
Weighted average diluted shares outstanding$63.4M$62M$61.3M$45M$35.4M
Balance sheet
20252024202320222021
Cash and short-term investments$352.3M$241M$236.2M$202.9M$218.2M
Net receivables$1.07M$3.34M$2.25M$1.08M$4.11M
Inventory$0.00$0.00$0.00$0.00-$-470K
Total current assets$357.5M$249.9M$242.2M$207.5M$226M
Property, plant and equipment, net$7.07M$9.58M$12.4M$16M$7.37M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$1.09M$1.09M
Total non-current assets$8.8M$10.8M$15.5M$19.2M$9M
Total assets$366.3M$260.7M$257.7M$226.7M$235M
Accounts payable$1.59M$1.16M$2.76M$3.64M$4.79M
Short-term debt$2.4M$2.19M$2.19M$2.6M$0.00
Deferred revenue$0.00$0.00$0.00$930K$4.71M
Total current liabilities$13.1M$11M$13.7M$16.7M$19.2M
Long-term debt$4.04M$6.44M$8.63M$10.8M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$200K$0.00
Total non-current liabilities$4.24M$6.64M$8.83M$11M$4.26M
Capital lease obligations$2.4M$8.63M$10.8M$10.8M$0.00
Total liabilities$17.3M$17.7M$22.5M$27.7M$23.5M
Common stock$70K$50K$60K$50K$40K
Retained earnings-$-594.28M-$-519.4M-$-509.67M-$-412.34M-$-302.47M
Accumulated other comprehensive income (loss)$170K$130K-$-140K-$-800K-$-400K
Total equity$349M$243M$235.2M$198.9M$211.5M
Total investments$154.8M$182.8M$210.7M$168.9M$183.8M
Total debt$6.44M$8.63M$10.8M$13.4M$0.00
Net debt-$-191.09M-$-49.58M-$-14.74M-$-21.68M-$-35.41M
Cash flow statement
20252024202320222021
Net income-$-74.88M-$-9.72M-$-97.33M-$-109.87M-$-80.85M
Depreciation and amortization$1.39M$1.59M$2.17M$2.41M$2.52M
Stock-based compensation$12.5M$14.6M$14.8M$13.4M$11.1M
Change in working capital$3.91M-$-4.25M-$-4.61M-$-3.09M-$-11.89M
Accounts receivable$2.1M-$-1.56M-$-310K$2.5M-$-500K
Inventory$0.00$0.00$0.00$0.00$1.25M
Accounts payable$430K-$-1.59M-$-850K-$-1.18M$970K
Net cash provided by operating activities-$-60.06M-$-2.22M-$-90.97M-$-97.05M-$-78.48M
Investments in property, plant and equipment-$-310K-$-280K-$-510K-$-1.96M-$-1.71M
Acquisitions, net$0.00$0.00$0.00-$-14.38M$128M
Net cash used for investing activities$30.7M$32.2M-$-36.69M$12.4M-$-129.67M
Common stock issued$168.7M$2.75M$117.3M$80.8M$182.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$168.7M$2.75M$118.1M$84.3M$186.5M
Net change in cash$139.3M$32.8M-$-9.54M-$-310K-$-21.64M
Cash at end of period$198.7M$59.4M$26.7M$36.2M$36.5M
Operating cash flow-$-60.06M-$-2.22M-$-90.97M-$-97.05M-$-78.48M
Capital expenditure-$-310K-$-280K-$-510K-$-1.96M-$-1.71M
Free cash flow-$-60.38M-$-2.5M-$-91.47M-$-99.01M-$-80.19M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Fulcrum Therapeutics, Inc.

        Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

        CEO
        Alexander C. Sapir
        Employees
        55
        Beta
        3.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Fulcrum Therapeutics, Inc. (FULC)?

        InvestorsCraft does not currently publish an intrinsic value for FULC. How the IC value is calculated.

        Is FULC undervalued?

        InvestorsCraft does not publish an undervaluation signal for FULC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.